PD-1 targeting in cancer immunotherapy

Authors

  • Robert Ferris MD, PhD


Division of Head and Neck Surgery, Cancer Immunology Program University of Pittsburgh Cancer Institute, 5117 Centre Ave, Hillman Research Wing, Room 2.26b, Pittsburgh, PA 15213. E-mail: ferrisrl@upmc.edu Fax: (412) 623-4840

Abstract

This Web-only perspective commentary discusses a new class of monoclonal antibodies that have garnered tremendous enthusiasm within the field of cancer immunotherapy, which has previously been hampered by complex, cumbersome agents and cells; individualized and laborious preparations; and questionable clinical efficacy.

Ancillary